This literature review addressed four questions. (1) In which populations other than cerebral palsy (CP) has the Gross Motor Function Classification System (GMFCS) been applied? (2) In what types of study, and why was it used? (3) How was it modified to facilitate these applications? (4) What justifications and evidence of psychometric adequacy were used to support its application? A search of PubMed, MEDLINE, and Embase databases (January 1997 to April 2017) using the terms: 'GMFCS' OR 'Gross Motor Function Classification System' yielded 2499 articles. 118 met inclusion criteria and reported children/adults with 133 health conditions/clinical descriptions other than CP. Three broad GMFCS applications were observed: as a categorization tool, independent variable, or outcome measure. While the GMFCS is widely used for children with health conditions/clinical description other than CP, researchers rarely provided adequate justification for these uses. We offer recommendations for development/ validation of other condition-specific classification systems and discuss the potential need for a generic gross motor function classification system.
The Gross Motor Function Classification System (GMFCS) 1 was created for use with children with cerebral palsy (CP). Its need arose from recognition of the heterogeneity of gross motor development and functioning among children with CP, and the value of stratifying children on the basis of their functional abilities and limitations as opposed to impairments in body functions such as muscle tone and reflexes. 1 Existing methods of motor classification, such as 'mild', 'moderate', and 'severe' impairment, were not standardized and lacked reliability and validity. 2 Since its publication in 1997, the GMFCS has become the international language to classify gross motor function of children with CP. 3 It has enhanced communication between families and professionals by providing standardized descriptions of gross motor function for each level and age band. 2 The five levels of the GMFCS describe children's typical performance at home and in the community, rather than their 'optimal' capacity observed during motor testing in a clinic setting. 1 Originally designed for children with CP aged 12 years and younger, the GMFCS was subsequently expanded and revised to include an age band for young people aged 12 to 18 years (GMFCS-ER). 4 Evidence of construct validity of the GMFCS was provided by the motor development curves for children and young people with CP. 5, 6 The differences in Gross Motor Function Measure-66 scores between children in each GMFCS level are statistically significant and clinically meaningful. 7 To evaluate stability of the GMFCS, 610 children were classified an average of 4.3 times at 6-month intervals over the course of this 4-year study. 8 The weighted kappa (j) coefficient was 0.84 for children younger than 6 years old and 0.89 for children 6 to 12 years of age, indicating excellent chance-corrected agreement. Seventy-three per cent of children remained in the same level for all ratings.
Although the GMFCS was developed and validated for children with CP, many investigators have used it to classify children with other health conditions/clinical descriptions. A previous scoping review on the uptake and clinical utility of the GMFCS 3 identified its use in children with acquired brain injury and children with Down syndrome. Misuses of GMFCS discovered in studies involving children with CP 3,9 also appear to be present in studies involving other populations. These 'off-label' uses both surprised and intrigued the authors and sparked the decision to embark on a literature review to determine the extent and nature of these occurrences. This literature review addressed four research questions, as follows. (1) In which conditions/clinical descriptions other than CP has the GMFCS been applied in published research? (2) In what types of study, for what purposes, and how has the GFMCS been used? (3) What modifications have been made to the GMFCS? (4) What evidence of reliability and validity has been provided to support use of the GMFCS for children with conditions/clinical descriptions other than CP? METHOD A literature search of PubMed, MEDLINE, and Embase databases from January 1997 to April 2017 was conducted by the first author (MT) with the search terms: 'GMFCS' OR 'Gross Motor Function Classification System'. Papers were screened by MT and included if participants with conditions/clinical descriptions other than CP had been classified with the GMFCS. Articles in languages other than English, conference posters or presentations, and articles for which a full version was unobtainable were excluded.
RESULTS
The literature search returned 4406 articles, 1611 from PubMed, 1262 from MEDLINE, and 1533 from Embase (see Table SI , online supporting information). Excluding 2354 duplicates, there were 2052 unique articles (Fig. 1) ; 1929 articles were excluded because they used the GMFCS to classify only people with CP; five articles were excluded because the sample description used ambiguous terminology (e.g. 'spasticity of cerebral origin'), [10] [11] [12] [13] [14] making it impossible to ascertain that they did not have CP. The final analysis was done with the 118 papers that satisfied the eligibility criteria.
GMFCS application: clinical populations and purposes for use
The 118 studies identified encompassed children and adults with 133 conditions/clinical descriptions other than CP (see Table SII , online supporting information). In these studies, the GMFCS was applied (1) to categorize and describe participants, or as an inclusion/exclusion criterion; (2) as an independent variable; (3) as a dependent variable in predictive studies; or (4) as an outcome measure in intervention studies. What this paper adds
Use to categorize or describe
• The Gross Motor Function Classification System should not be used outside cerebral palsy or as an outcome measure.
• The authors provide recommendations for development and validation of condition-specific or generic classification systems.
only to define eligibility criteria. [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] While reliability and validity of GMFCS have been demonstrated in children with CP, 1,4 none of these articles reported reliability or validity of these GMFCS categorizations in other conditions/clinical descriptions.
Use as an independent variable
Six studies compared the GMFCS with another measure to evaluate the other measure's validity. [55] [56] [57] [58] [59] [60] For example, one examined the strength of association between GMFCS level and the Trunk Control Measurement Scale score to evaluate the latter's construct validity. 57 In four studies, 56 ,61-63 participants were stratified by GMFCS level, and measurement properties (i.e. responsiveness, test-retest reliability, and floor and ceiling effects) of the measure of interest (e.g. the modified Berg Balance Scale) 63 were reported by GMFCS level.
The GMFCS was used as a grouping variable in three studies to determine the discriminant validity of another measure. 55, 57, 60 For example, discriminant validity of the Timed Up and Go test was examined by observing differences between mean Timed Up and Go scores across GMFCS levels. 60 Four studies used the GMFCS as a grouping variable to present data from other measures. [64] [65] [66] [67] Fourteen prospective cohort or retrospective studies used the GMFCS as an independent variable, predictor, or covariate 65, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] to determine whether GMFCS levels were associated with other characteristics such as bone density and fractures. 80 
Use as a dependent variable in predictive studies
Five predictive studies used the GMFCS as the dependent variable to determine whether another measure administered at an earlier time point could predict future GMFCS level. 59, 72, [81] [82] [83] For example, Rose et al. 59 assessed the predictive validity of diffusion tensor imaging fractional anisotropy in preterm and very low birthweight children by evaluating the association between diffusion tensor imaging results at 37 weeks gestational age and GMFCS level at 4 years.
Use as an outcome measure
Thirteen intervention studies of children with conditions/ clinical descriptions other than CP 64,84-95 tracked baseline and postintervention GMFCS levels, and reported the number of participants who changed levels and the number of levels changed (e.g. two levels if reclassified from level IV to level II). For example, in the acute stages of paediatric stroke, all 44 participants (ages 8mo-17y) were reclassified to a lower GMFCS level (higher function) on average 2 months after stroke. 90 Three other studies compared GMFCS levels between two experimental groups after an intervention without recording a baseline level. [96] [97] [98] Acknowledgement of the purpose and measurement properties of the GMFCS Among the 118 papers, 76 did not mention that the GMFCS was developed specifically for use with children with CP or discuss its measurement properties. 64, 65, 67, 68, [70] [71] [72] [73] [74] [75] [76] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] 92, Twenty noted that the GMFCS was created for children with CP but did not justify its application to their condition/clinical description. Ten papers acknowledged that the GMFCS was designed for children with CP and provided justification (see Table SI ' The GMFCS has been found to be valid and reliable for this proposal' 51 was noted while referencing studies of children with CP, rather than those with Down syndrome for whom it was being used.
17-
23,25-27,29,30,33-35,37,40,42-45,48-52,54,
Modifications of the GMFCS for children who do not have CP
In 38 studies, the five GMFCS levels were collapsed into two or three broader groups (e.g. levels I, II, and III combined under the title of 'ambulatory' participants and levels IV and V combined under the title of 'non-ambulatory' participants). 22, 24, 25, 40, 61, 65, 69, 70, 72, 74, 75, [77] [78] [79] [80] [82] [83] [84] 91, [96] [97] [98] 101, 103, [107] [108] [109] [110] [111] [113] [114] [115] [123] [124] [125] [126] 129, 130 In one study involving children with CP, closed-head injury, learning disability, or developmental delay, merging of levels (i.e. I and II) was reportedly undertaken to allow 'reliable retrospective scoring'. 25 Others stated that levels were combined to accommodate small sample sizes within each level. 91, 126, 130 The other articles did not provide any rationale for combining levels.
Two related studies modified the descriptors of GMFCS levels I and II. 62, 63 Children who could run/jump were classified in level I, and those who could not were classified in level II. This was to accommodate a lack of spontaneous running or jumping in people with visual deficits. 72 
DISCUSSION
This literature review confirmed the authors' impressions that (1) the GMFCS is being used with children who do not have CP and (2) has been applied for purposes that have not been validated. This indicates that there is a perceived need for a system to classify gross motor function of children with conditions/clinical descriptions other than CP. A considerable number of articles reviewed made misleading or inaccurate statements to support their application of the GMFCS, perpetuating its 'off-label' use. Unfortunately, these broader applications contradict the underlying conceptual basis of the GMFCS, and fail to recognize the need for evidence of its measurement properties with respect to the condition/clinical description being classified.
The five levels of the GMFCS were constructed according to expert consensus to represent clinically meaningful distinctions in daily mobility-based functioning specifically, and only, in children with CP. 133 Subsequent research validated the meaningfulness (validity) of these five levels. 5 The age bands reflect development of gross motor function of children and young people with CP. The application to children with other congenital or acquired neurodevelopmental or orthopaedic conditions, or conditions that are progressive, has not been validated. There is no assurance that these same levels apply to children with other congenital or acquired conditions given the nature of various underlying impairments and disease processes and their potential impact on children's development and abilities. For example, children with acquired brain injury have, on average, greater Gross Motor Function Measure change scores than children with CP. 134 Children with Down syndrome also demonstrate different motor growth curves on the Gross Motor Function Measure than children with CP, indicating different patterns of development and the importance of describing these systematically. 135 Some misuses of the GMFCS warrant further discussion. Many studies used the GMFCS in ways we believe are inappropriate, without recognizing (or at least indicating) the serious risks to their interpretations associated with basing study conclusions on a tool with questionable validity for their clinical group(s). When describing gross motor function of a child using the GMFCS, evidence is needed of both reliability and validity for that condition/clinical description before use. Adequate reliability and validity for other conditions/clinical descriptions are not certain given the likely issues of lack of direct functional content/conceptual fit.
A common practice was to collapse the five levels of the GMFCS into two or three subgroups. This might be appropriate at times, such as when investigators are trying to distinguish between ambulatory and non-ambulatory participants. In many studies, however, this collapse was probably used to facilitate statistical analysis, as the number of participants in one or more of the five levels was very small. Rationale or justification for the subgroups created was not always provided, a potential threat to internal validity.
Finally, while use of GMFCS level as a predictor variable within regression analysis or as an 'outcome indicator' within a discriminant function analysis is acceptable, the GMFCS should never be used as an outcome variable, whether participants have CP or another condition/clinical description. The GMFCS was not developed, and has never been validated, for this purpose, but other tools have. For example, the Gross Motor Function Measure is an evaluative measure that has been validated to measure change over time or in response to an intervention in children with CP and children with Down syndrome. 7 Two papers demonstrated potential measurement-related issues with use of the GMFCS in children with Down syndrome and children with mucopolysaccharidosis. 128, 130 Bodkin et al. 128 evaluated interrater reliability, criterion, and construct validity with 50 children (23 with CP and 27 with Down syndrome). They reported a value of j of 0.84, with no disagreements greater than one level, and moderate correlation with age-equivalent scores on the Peabody Gross Motor Scale. However, by the time the children with Down syndrome were just over 2 years of age, 21 of the 24 children for whom a GMFCS level was assigned at this age (three participants were not classified at this point) were classified in GMFCS level I. This suggests a ceiling effect and serious content validity issues as the other four GMFCS levels may not have applied to this group of children. Indeed, the authors concluded that while GMFCS level could be reliably assigned in children with Down syndrome, and younger children displayed some variability on the GMFCS, it was of little use in classifying the older children because of the lack of variability.
Matos et al. 130 assessed GMFCS reliability and construct validity in 22 children with mucopolysaccharidosis. While it had excellent intra-and interrater reliability in this group, and could differentiate limitations in motor function among these children, there were issues with scientific rigour that compromised the strength and interpretation of the results. 130 Furthermore, while acknowledging the differences in clinical course between this progressive degenerative condition and CP, the authors did not indicate how these differences might influence the suitability of the GMFCS, or what research questions could and could not be answered with this application of the GMFCS. 130 This reinforces the need to evaluate face and content validity before the GMFCS is used 'off label', followed by reliability and further validity testing for the specific research question being addressed.
Kehrer et al. 136 developed the Gross Motor Function Classification in metachromatic leukodystrophy (GMFC-MLD), on the basis of the conceptual ideas and structure of the GMFCS, for classification of individuals with paediatric metachromatic leukodystrophy (MLD). There are three forms of MLD based on age at onset (late infantile, juvenile, and adult onset), and each follows a similar course of progressive motor deterioration. Thus, unlike the GMFCS, the GMFC-MLD was not designed to stratify children's functional abilities by age. 136 The number of levels and the descriptions are based on data from 59 individuals with MLD, including hospital records, physicians' reports, and standardized patient questionnaires. Because children with MLD experience typical development before diagnosis, the GMFC-MLD incorporates a level 0 to indicate typical development and describe the loss of function. Since MLD is characterized by a rapid deterioration of motor function, mobility aids are uncommon and were not included in the criteria for functional levels. Additionally, on the basis of recent development of therapeutic options for MLD, the authors suggest that the GMFC-MLD might be used to monitor changes in motor function over time. 136 Since MLD is rare, the GMFC-MLD was designed so that specialist clinicians, who may see these children infrequently, could assign a level using descriptions of motor function from medical records of local clinicians who follow these children more regularly. 136 The authors were able to establish interrater reliability of the GMFC-MLD 136 but other psychometric properties related to its function as a classification and outcome measure have yet to be reported.
CONCLUSION
In summary, the many applications reviewed were not congruent with the GMFCS's intended purpose, and evidence of reliability and validity was not provided. The GMFCS should not be used with children who do not have CP or with children under the age of 1 year, as it was not validated within this age range. Furthermore, researchers need to consider carefully their research question, and determine the type of measure(s) or tools(s) required to answer the question, then decide whether a classification system is appropriate. If the research question requires an outcome measure, it is important to keep in mind that the GMFCS was neither developed nor intended as an outcome measure. It lacks both the structural and measurement properties to serve as an outcome measure and should never be used as one.
The extensive uptake of the GMFCS across diagnostic groups suggests the need for other condition-specific classification systems or a more generic gross motor function classification system that could be applied broadly across children with different conditions. The GMFC-MLD by Kehrer et al. 136 is an example of how the framework of the GMFCS might be used to develop and then validate a condition-specific classification system for children with conditions/clinical descriptions other than CP. The nominal group and Delphi survey expert consensus methods used to establish content and construct validity of the GMFCS have been described and could be applied as a basis for its development. 1, 4 If a generic gross motor function classification system that is non-specific to any health condition were to be developed, it would probably expand function to include gross motor recreation and sport activities.
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SUPPORTING INFORMATION
The following additional material may be found online: Table SI : Articles in which children or adults who did not have cerebral palsy were classified using the Gross Motor Function Classification System Table SII : Clinical populations other than cerebral palsy for which Gross Motor Function Classification System has been used 
